Pirfenex
Utilised to manage fibrotic tissue buildup to alleviate lung scarring and support pulmonary capacity.
- Category
- Pain & Anti-inflammatories
- Active ingredient
- Pirfenidone
- Route
- Oral use
- Form
- Tablet
- Strengths
- 200mg · 400mg · 600mg · 801mg
Prescription and consultation requirements for Pirfenex vary by destination and are determined by the fulfilment partner.
Pirfenex details
- Condition
- Idiopathic Pulmonary Fibrosis
- Alternative names
- pirfenidone
- Therapeutic class
- Antifibrotic Agent
- Pharmacological class
- Pyridone Antifibrotic
- Minor side effects
- nausea; vomiting; photosensitivity
- Moderate side effects
- skin rash; fatigue; dyspepsia
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 2–4 weeks
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Fluvoxamine; Ciprofloxacin; Tobacco
- Age restrictions
- Approved for adults.
Contraindications
severe hepatic impairment; severe renal impairment requiring dialysis; concurrent fluvoxamine use
Serious side effects
severe drug-induced hepatotoxicity, requires immediate medical attention; angioedema, requires immediate medical attention
Patient summary
utilised to manage fibrotic tissue buildup to alleviate lung scarring and support pulmonary capacity.
Mechanism of action
Suppresses synthesis of transforming growth factor-beta and tumour necrosis factor-alpha, stopping collagen accumulation inside tissues.
Pregnancy and breastfeeding
TGA Category C: Limited clinical records. Avoid in pregnancy. Breastfeeding: Consult a doctor.